From October 7 to 10, 2026, LIFE ORIFIN participated in the 38th Hospital Expo 2026 (Indonesia International Hospital Exhibition). The company showcased its product portfolio and technical expertise in the field of in vitro diagnostics (IVD), engaged in in-depth exchanges with on-site customers, and proactively identified overseas market demands.
Exhibition Overview
Hosted at the BSD City International Convention and Exhibition Center in Indonesia, Hospital Expo is a leading, high-impact professional medical industry event in Southeast Asia. This edition spans a total exhibition area of 36,910 square meters across 6 exhibition halls with 960 standard booths, gathering 625 exhibitors and institutions from around the world. Exhibits cover the full medical industry chain, including diagnostic equipment, laboratory reagents, smart healthcare, rehabilitation and nursing care, etc. Over the four-day event, the expo drew more than 60,000 professional visitors, serving as a core platform for medical enterprises to expand into Southeast Asian markets and connect with industry resources.
Product Highlights
At this expo, LIFE ORIFIN presented products from its three core technology platforms: biochemistry, chemiluminescence, and point-of-care testing (POCT). The portfolio includes diagnostic reagents and supporting testing solutions covering multiple clinical fields such as cardiovascular diseases, metabolic disorders, and respiratory tract infections.
Among the exhibits, the respiratory product series — tailored to local clinical needs — received significant attention from on-site customers. Numerous professional visitors held in-depth discussions with the team on product performance, application scenarios, and cooperation models, laying a solid foundation for further market alignment and the implementation of cooperation intentions going forward.
AI Innovation & Development
Artificial intelligence is unlocking brand-new development opportunities for the healthcare sector. Embracing the AI era, LIFE ORIFIN will continue to focus on the integration of artificial intelligence and in vitro diagnostic technologies. Building on its existing product and technology foundation, the company will explore AI applications in scenarios including R&D, testing process optimization, quality management, and service improvement, driving the iterative upgrading of products and services through technological innovation.
Leveraging the strengths of its integrated “raw materials – reagents – services” industrial chain, the company will keep pace with clinical and market demands, advance product innovation and service capacity building, and deepen international exchanges and cooperation. With an open mindset, LIFE ORIFIN will jointly explore new opportunities in the IVD field with partners at home and abroad.
Post time: Oct-16-2026